The American Diabetes Association (ADA) wants to help you understand time in range (TIR) as a new blood glucose management measure and implement it with the appropriate patients today. For many people with diabetes, blood glucose monitoring is key for achieving glycemic targets. Self-monitoring of blood glucose is an integral component of effective therapy of patients taking insulin. In recent years, continuous glucose monitoring (CGM) has emerged as a complementary method for assessing blood glucose levels. CGM accuracy and affordability has evolved rapidly and many patients have these data available to assist with both self-management and assessment by providers. Reports can be generated from CGM that will allow the provider to assess hypoglycemia, hyperglycemia, and glycemic variability plus determine TIR.
Below are resources to help patients and clinicians use TIR data to make informed treatment and lifestyle decisions that improve health outcomes.
Get the latest diabetes technology and time in range guidelines based on the ADA Standards of Care in Diabetes—2023. Watch our webinars, download infographics, and listen to our podcasts and Practice Pearls to help you understand and implement TIR practice recommendations. Get Started Now.